XML 14 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Interim Statements of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating activities    
Net loss $ (1,550,000) $ (7,673,000)
Add items not affecting cash    
Share-based compensation 1,420,000 2,681,000
Deferred income tax benefit (567,000)  
Foreign exchange loss (gain) 2,000 (124,000)
Investment loss from joint ventures 984,000  
Fair value gain on Investment in Aqualung (2,990,000)  
Fair value gain on financial asset - FID (741,000) 0
Amortization 332,000 289,000
Interest expense 10,000 14,000
Other 6,000  
Net changes in non-cash working capital items:    
Other current assets (1,460,000) (1,522,000)
Advances and deposits   (19,000)
Accounts payable and accrued liabilities 91,000 775,000
Receivables - related parties (1,916,000)  
Accounts payable - related parties (121,000)  
Net cash used in operating activities (6,500,000) (5,579,000)
Investing activities    
Exploration and evaluation assets (3,000) (5,131,000)
Change in restricted cash 58,000  
Patent (20,000)  
Net cash provided by (used in) investing activities 35,000 (5,131,000)
Financing activities    
Proceeds from issuance of shares 7,197,000 11,110,000
Share issuance costs (204,000) (446,000)
Lease payments (101,000) (110,000)
Net cash provided by financing activities 6,892,000 10,554,000
Effect of exchange rates on cash (35,000) 71,000
Net change in cash 392,000 (85,000)
Cash, beginning of period 31,177,000 11,690,000
Cash, end of period $ 31,569,000 11,605,000
Non Cash Investing Activities [Abstract]    
Change in exploration and evaluation expenditures included in accounts payable   $ (721,000)